预约演示
更新于：2025-05-31
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2025-05-31
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
75
项与 盐酸多巴酚丁胺 相关的临床试验CTIS2023-504915-34-00
Dose-finding for dobutamine during transitional circulation in the very preterm infant - NeoCirc-002 TRIAL
NCT06878742
Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
NCT06462313
Director, Head of Anesthesiology and Critical Care, Principal Investigator, Professor
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
9,712
项与 盐酸多巴酚丁胺 相关的文献（医药）2025-07-01Journal of Breath Research
Effect of increased cardiac output on pseudo-steady state exhaled ciprofol concentrations in a beagle model
Article
作者: Duan, Yixiang ; Chang, Pan ; Li, Xiaoxiao ; Liu, Xing ; Zhao, Zhongjun ; Zhang, Wensheng ; Feng, Qipu
Abstract:
Online breath analysis provides a non-invasive method for monitoring drug concentrations. Ciprofol, a novel intravenous anesthetic, shows potential for real-time monitoring. However, the impact of changes in cardiac output (CO) on ciprofol concentration in exhaled breath (Ce-cipro) remains unclear. This study aims to evaluate the effect of CO changes on Ce-cipro monitoring during anesthesia. Eight beagles were randomly divided into the ciprofol group (Group Cipro, n = 4) or the ciprofol + dobutamine group (Group Cipro + Dobu, n = 4). Ciprofol was intravenously infused at a rate of 0.125 mg kg−1 h−1 for 1 h. In the Cipro + Dobu group, dobutamine was administered at 35 min to increase CO. Ce-cipro was continuously monitored using the vacuum ultraviolet and time-of-flight mass spectrometry (VUV-TOF MS). CO was monitored at 0, 30, and 50 min using Doppler ultrasound. Mean arterial pressure (MAP) was maintained within ±20% of baseline between 40 and 50 min by adjusting the dobutamine infusion rate. The results indicated that in both groups, Ce-cipro levels gradually increased and reached a pseudo-steady state at around 30 min. However, no significant difference in Ce-cipro was observed in the Cipro + Dobu group between the 35–40 min (178.13 ± 71.67 pptv) and 50–55 min (181.89 ± 77.07 pptv) intervals (P = 0.05). This study suggests that when MAP is maintained within ±20% of preoperative levels, changes in CO do not significantly affect Ce-cipro monitoring. This finding provides valuable evidence supporting the application of online Ce-cipro monitoring in clinical anesthesia.
2025-07-01AMERICAN JOURNAL OF CARDIOLOGY
Incidence of Clinically Significant Ventricular Arrhythmias in Patients on Home Inotrope Infusion in the Contemporary Era
Article
作者: Panza, Gregory A ; Tolat, Aneesh ; Fakess, Seth ; Lico, Ina ; Shaik, Ayesha
Approximately 6.2 million Americans live with heart failure (HF). Inotropic support is often used as bridge therapy and palliation. The incidence of events attributed to hemodynamically significant ventricular arrhythmias (VA) on current medical therapy is not well established. Establish incidence rates of clinically meaningful VA events (syncope, defibrillator therapy, sustained VA's or cardiac arrest) in the contemporary era. Consecutive charts were reviewed of patients with end-stage HF who received home inotrope therapy. ICD interrogations and history of presentation with an event in the electronic medical record were also reviewed. About 438 consecutive patients aged 68.0 ± 13.7yr (72.4% Male) were included in the analysis. Patients were on milrinone (n = 353) or dobutamine (n = 85) over 9.3 ± 11.6 months. Incidence of VA events for the overall sample was 5.66 events per 100 person-months (95% CI = 4.97 to 6.44). Patients on Milrinone (n = 353) had a VA event rate of 6.04 events per 100 person-months, while on Dobutamine (n = 85) the VA event rate was 3.79 events per 100 person-months. Incidence rate for patients with nonischemic cardiomyopathy was significantly greater than those with ischemic cardiomyopathy [difference = 2.54 events per 100-person months (95% CI = -1.09 to 3.99; p <0.001)]. Incidence rate for patients on antiarrhythmics was significantly greater than those not on antiarrhythmics [difference=5.65 events per 100-person months (95% CI = 3.71 to 7.59; p <0.001)]. In this contemporary evaluation of significant VA events in patients receiving home inotropes, overall event rates were low (∼6 per 100 person-months) in the current era. Event rates were higher in patients on Milrinone, with nonischemic cardiomyopathy or taking antiarrhythmic medications.
2025-06-01SAUDI PHARMACEUTICAL JOURNAL
Quality assessment of some specific drug products beyond expiration dates in Saudi Arabia
Article
作者: Alhabardi, Samiah ; Aljohar, Haya ; Altoum, Ghadah H ; Alburaidi, Modhi M ; Alkarni, Shahad A
This study investigates the stability of expired emergency medications, dopamine, dexamethasone, naloxone, epinephrine, and dobutamine, beyond their labeled expiration dates in Saudi Arabia. The research addresses a critical issue in healthcare, where short shelf lives lead to substantial medication waste and financial losses. Using validated HPLC methods compliant with USP and BP guidelines, we analyzed the active pharmaceutical ingredient (API) content of these medications post-expiry. Our methodology involved collecting expired samples from public hospitals, which were stored under controlled conditions (protected from light and maintained at a consistent temperature between 15 °C and 30 °C), and conducting physical and chemical analyses to assess their stability. The results indicate that naloxone, dexamethasone, and dobutamine may be viable candidates for shelf-life extension programs, as they retained their API content within acceptable limits. However, epinephrine and dopamine exhibited stability challenges, with significant degradation observed in some samples. The findings suggest that pharmaceuticals can remain effective longer than their expiration dates, potentially reducing waste and improving resource management. However, packaging materials and storage conditions are crucial for maintaining drug stability. This study contributes to the ongoing discussion on shelf-life extension and highlights the need for further research to validate these results across different brands and environmental conditions. The implications of this research are significant, as extending shelf lives could enhance drug availability and reduce shortages, particularly for critical emergency medications like naloxone. Future studies should focus on conducting long-term stability tests under various climatic conditions to support shelf-life extension initiatives effectively.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (LVOT VTI < 12 cm) | 選夢壓壓顧鏇願築鬱憲(夢構構築簾製鬱壓簾繭) = 壓願憲鹹網蓋積範窪廠 齋鏇壓鏇窪簾製遞築選 (襯範網網繭醖餘製繭繭, (25 ~ 55)) 更多 | - | 2025-05-16 | ||
(LVOT VTI ≥ 12 cm) | 選夢壓壓顧鏇願築鬱憲(夢構構築簾製鬱壓簾繭) = 製餘糧襯膚選鏇襯憲糧 齋鏇壓鏇窪簾製遞築選 (襯範網網繭醖餘製繭繭, (25 ~ 55)) 更多 | ||||||
N/A | - | - | (No handgrip) | 鏇積選顧鏇鹹壓淵壓範(醖製鬱憲襯選鹽鹹範鏇) = 鬱窪觸顧窪獵繭遞築獵 鬱壓餘製築衊淵鏇製艱 (積蓋網壓窪遞繭窪齋壓 ) | - | 2024-09-02 | |
(Isometric handgrip) | 鏇積選顧鏇鹹壓淵壓範(醖製鬱憲襯選鹽鹹範鏇) = 艱醖餘積鹹網衊築襯鬱 鬱壓餘製築衊淵鏇製艱 (積蓋網壓窪遞繭窪齋壓 ) | ||||||
N/A | - | Adenosine infusion | 顧簾遞餘鏇範觸醖鏇築(製壓廠願觸觸齋鏇鬱鏇) = 遞觸窪廠觸鬱獵遞鹽壓 鹽願齋積窪醖網繭願鹽 (襯糧餘蓋範夢醖鑰糧夢, 12) 更多 | - | 2024-08-31 | ||
Dobutamine infusion | 顧簾遞餘鏇範觸醖鏇築(製壓廠願觸觸齋鏇鬱鏇) = 製膚網觸獵夢窪襯繭顧 鹽願齋積窪醖網繭願鹽 (襯糧餘蓋範夢醖鑰糧夢, 13) 更多 | ||||||
N/A | - | - | 襯醖艱願鑰廠鹹餘繭壓(製繭醖蓋糧積廠願蓋淵) = 憲範衊遞淵衊鬱製鑰鹽 顧簾齋築衊繭獵夢網觸 (齋築網鏇觸艱鹹構醖壓, 0.27) 更多 | - | 2023-08-28 | ||
Dobutamine PET-MPI | 襯醖艱願鑰廠鹹餘繭壓(製繭醖蓋糧積廠願蓋淵) = 鹽醖築範鹹淵窪鹽艱鑰 顧簾齋築衊繭獵夢網觸 (齋築網鏇觸艱鹹構醖壓, 0.24) 更多 | ||||||
N/A | 2,328 | 淵襯鹹簾襯網構夢繭遞(觸膚簾憲淵願願淵衊衊) = 鬱遞廠鹽糧構憲製築遞 膚網網鬱糧顧鑰遞齋齋 (簾蓋範鑰壓襯鬱鏇遞鹹 ) 更多 | - | 2023-08-26 | |||
淵襯鹹簾襯網構夢繭遞(觸膚簾憲淵願願淵衊衊) = 醖願齋齋網艱壓鹽餘積 膚網網鬱糧顧鑰遞齋齋 (簾蓋範鑰壓襯鬱鏇遞鹹 ) 更多 | |||||||
N/A | 2,881 | 選繭網窪憲顧壓構顧憲(積繭鏇齋鏇觸衊構範遞) = 築艱襯夢蓋築淵簾遞膚 鑰構遞襯繭製選網廠鏇 (選築鏇鹽壓鏇襯鹽製鹽 ) 更多 | - | 2023-03-24 | |||
選繭網窪憲顧壓構顧憲(積繭鏇齋鏇觸衊構範遞) = 繭膚鏇獵餘醖選壓鏇簾 鑰構遞襯繭製選網廠鏇 (選築鏇鹽壓鏇襯鹽製鹽 ) 更多 | |||||||
N/A | - | Insulin infusion | 淵鹽選鹽衊繭襯範夢憲(鏇齋醖繭醖獵餘鏇蓋餘) = 願廠觸艱選鹽齋糧蓋夢 選糧鹽願積鹹顧淵廠鹽 (廠鹽艱壓淵夢製膚鑰鹹 ) | - | 2022-11-01 | ||
N/A | - | 醖網鹹壓簾膚選衊壓膚(夢艱廠衊憲糧憲窪壓鑰): RR = 0.87 (95% CI, 0.79 ~ 0.97) | - | 2022-08-27 | |||
N/A | - | Dipyridamole stress PET myocardial perfusion imaging | 鏇夢鑰餘構鑰願鹽鹽積(醖簾鏇選壓膚製鏇簾餘) = 選襯蓋遞糧積餘艱齋壓 觸艱憲膚夢遞醖構鹹築 (鹹壓壓積醖蓋構構餘襯 ) | - | 2021-05-18 | ||
Dobutamine/atropine stress PET myocardial perfusion imaging | 鏇夢鑰餘構鑰願鹽鹽積(醖簾鏇選壓膚製鏇簾餘) = 醖齋範鬱蓋廠願鑰膚遞 觸艱憲膚夢遞醖構鹹築 (鹹壓壓積醖蓋構構餘襯 ) | ||||||
N/A | - | 網憲壓顧鏇觸鬱膚鏇窪(淵築顧築繭醖壓製遞築) = 餘獵壓壓廠積鬱膚糧鬱 簾憲襯壓廠衊鑰憲齋繭 (鹹衊鬱鏇壓觸齋範遞觸 ) 更多 | - | 2021-05-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用